The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI), to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18-70) years. The phase-II trials is planned to conduct with 500 participants from the age group (18-75) years. On 24 August 2021, the Drugs Controller General of India gave a go ahead for phase II/III trials after it was found to safe, tolerable, and immunogenic in the phase I trial results.
HGC019
IEC 62304
EPI-001
SmeT
MVA-B
Southern Cross group 
ESKAPE
ID2020